Acknowledgements
Cancer
ONCOLOGY, ADVANCED CANCER, CANCER
Medical writing support was provided by Tina Ippolito, an independent consultant funded by Sierra Oncology. Andrew Dye, an employee of Sierra Oncology also provided medical writing support and data curation. Bryan Strouse, an employee of Sierra Oncology also contributed to data curation for this report. UK clinical trial sites acknowledge infrastructural funding from Experimental Cancer Medical Centres and National Institute of Health and Care Research Biomedical Research Centres. The Institute of Cancer Research, London, UK (ICR)/Royal Marsden Hospital (RMH) in addition acknowledge Cancer Research UK funding to Cancer Centre Funding and funding to the Cancer Therapeutics Unit. U. Banerji is a recipient of the NIHR RP-2016-07-028. Preliminary data presented at annual meeting of the American Society of Clinical Oncology (31-May to 04-June 2019, Chicago, Illinois, USA) in abstract 3094 entitled: A first-in-human Phase I/II trial of SRA737 (a Chk1 inhibitor) in subjects with advanced cancer [